Breaking News Instant updates and real-time market news.

VTL

Vital Therapies

$5.60

-0.2 (-3.45%)

16:16
03/13/18
03/13
16:16
03/13/18
16:16

Vital Therapies CEO says nears completion for VTL-308

"As VTL-308 nears completion, I am proud of the job our team has done in designing and running this pivotal trial," said Russell J. Cox, the company's CEO. "Not only do baseline characteristics of subjects continue to track closely to the reference population, but also, blended event rates were found to be consistent with our modeled expectations. We look forward to reporting topline results in the third quarter, and in the event of a positive outcome, preparing to file a biologics license application next year."

  • 13

    Mar

  • 03

    May

VTL Vital Therapies
$5.60

-0.2 (-3.45%)

05/18/17
RAJA
05/18/17
INITIATION
Target $6
RAJA
Outperform
Vital Therapies initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Vital Therapies with an Outperform and a $6 price target saying the the current pivotal VTL-308 Phase 3 study presents the opportunity to definitively determine if ELAD can improve survival outcomes among patients with acute alcoholic hepatitis and thinks it could be of interest for risk/tolerant investors, assuming approval.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.